Zobrazeno 1 - 10
of 108
pro vyhledávání: '"A.W.S. Ritchie"'
Autor:
Malcolm David Mason, Martin J. Russell, Daniel M. Aebersold, Mahesh K. B. Parmar, Clare Gilson, David Matheson, Simon Chowdhury, Robert Jones, Silke Gillessen, William Cross, Hassan Douis, Adnan Ali, Alex Hoyle, Gerhardt Attard, A.W.S. Ritchie, Christopher D. Brawley, Johann S. de Bono, Chris Parker, David P. Dearnaley, Fiona C. Ingleby, Noel W. Clarke, Adrian Cook, Matthew R. Sydes, Nicholas D. James, Robin Millman
Publikováno v:
European Urology. 76:719-728
Background Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naive prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the STAMPEDE trial. There remains u
Autor:
Tim Eisen, Bhavna Oza, Joaquim Bellmunt, Axel Bex, Janet E. Brown, Mahesh K. B. Parmar, Martin R. Stockler, Richard Kaplan, Barry W. Hancock, Ian D. Davis, Gregers G. Hermann, James Larkin, Steven Joniau, A.W.S. Ritchie, Jim Barber, Rhona McMenemin, Lisa Pickering, Angela M. Meade, Paul Nathan, Eleni Frangou, Elizabeth Hodgkinson, Bernard Escudier, Grant D. Stewart, Benjamin Smith, Laurence Albiges
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(34)
PURPOSE SORCE is an international, randomized, double-blind, three-arm trial of sorafenib after surgical excision of primary renal cell carcinoma (RCC) found to be at intermediate or high risk of recurrence. PATIENTS AND METHODS We randomly assigned
Autor:
Janet E. Brown, J.M. Russell, Hassan Douis, Adrian Cook, Matthew R. Sydes, David Matheson, Narayanan Srihari, Alex Hoyle, Matthew S. Simms, A. Nikapota, Anjali Zarkar, Christopher D. Brawley, F.C. Ingleby, Noel W. Clarke, J. Calvert, John Wagstaff, Duncan C. Gilbert, Gerhardt Attard, Jacob Tanguay, A.W.S. Ritchie, Adnan Ali, Ruth E Langley, Andrew Protheroe, Aurelius Omlin, H. Rush, Anna Lydon, David P. Dearnaley, Malcolm David Mason, James D. Wylie, Silke Gillessen, Simon Chowdhury, L. Capaldi, Sharon Beesley, Joe M O'Sullivan, Mona Parmar, Omi Parikh, Joanna Gale, Jan Wallace, S. Rudman, Chris Parker, Alison Birtle, Archie Macnair, Claire Amos, Stephanie Gibbs, Robin Millman, Robert Jones, Zafar Malik, William Cross, Nicholas D. James, Shaun Tolan
Publikováno v:
STAMPEDE Investigators 2019, ' Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial ', Annals of Oncology . https://doi.org/10.1093/annonc/mdz396
Annals of Oncology
Annals of Oncology
Background\ud \ud STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcome
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae50219cab2735395675e6bd870c6e64
https://doi.org/10.1093/annonc/mdz396
https://doi.org/10.1093/annonc/mdz396
Autor:
Duncan C. Gilbert, Joanna Gale, Nicholas D. James, Shaun Tolan, Claire Amos, Robin Millman, Zafar Malik, G. Attard, James D. Wylie, Anjali Zarkar, S. Rudman, Robert Jones, Anna Lydon, Noel W. Clarke, Chris Parker, Joe M O'Sullivan, Jan Wallace, Aurelius Omlin, Alison Birtle, Adrian Cook, Archie Macnair, Malcolm David Mason, A.W.S. Ritchie, Matthew S. Simms, Alex Hoyle, Adnan Ali, H. Rush, John Wagstaff, Christopher D. Brawley, Jacob Tanguay, Andrew Protheroe, Silke Gillessen, Ruth E Langley, F.C. Ingleby, Omi Parikh, Stephanie Gibbs, David P. Dearnaley, David Matheson, Matthew R. Sydes, William Cross, Simon Chowdhury, L. Capaldi, Sharon Beesley, J. Calvert, Janet E. Brown, J.M. Russell, Hassan Douis, Narayanan Srihari, A. Nikapota, Mona Parmar, Stampede Investigators
Publikováno v:
Annals of Oncology. 31:442
Autor:
Axel Bex, Eleni Frangou, Barry W. Hancock, Laurence Albiges, Gregers G. Hermann, Angela M. Meade, Martin R. Stockler, Tim Eisen, Ian D. Davis, Benjamin Smith, Elizabeth Hodgkinson, Bernard Escudier, M.K.B. Parmar, Bhavna Oza, Joaquim Bellmunt, P. Hanlon, J.M.G. Larkin, Steven Joniau, A.W.S. Ritchie, Richard Kaplan
Publikováno v:
Annals of Oncology. 30:v891-v892
Background SORCE is a randomised, double-blind trial of sorafenib after surgical excision of primary renal cell carcinoma (RCC) at intermediate or high risk of recurrence (Leibovich classification). Methods We recruited patients from 147 sites in the
Autor:
Alex Hoyle, Chris Parker, Nicholas D. James, Robert Jones, A. Cooke, Silke Gillessen, Martin J. Russell, G. Attard, J.S. de Bono, N.W. Clarke, Matthew R. Sydes, William Cross, David P. Dearnaley, Hassan Douis, M.K.B. Parmer, Clare Gilson, Simon Chowdhury, A.W.S. Ritchie, Adnan Ali, Malcolm David Mason, David Matheson
Publikováno v:
European Urology Supplements. 18:e1387-e1388
Autor:
Ian D. Davis, Xanthi Coskinas, Shomik Sengupta, A.W.S. Ritchie, Richard Kaplan, Prunella Blinman, Martin R. Stockler, Angela M. Meade, Andrew J. Martin, Tim Eisen, S. Troon, Elizabeth Hovey
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 29(2)
Background We sought to determine the survival benefits that patients judged sufficient to warrant adjuvant therapy with sorafenib for 1 year, or for 3 years after resection of renal cell carcinoma in the SORCE trial. Methods SORCE participants from
Publikováno v:
European urology. 72(1)
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 28(10)
Madam — Tanguay and colleagues presented data on patients treated with docetaxel [1]. We agree that the reported rates of neutropenia-based toxicities vary across the trials, as do the categories against which toxicities are reported.
Autor:
Matthew R. Sydes, David Matheson, David P. Dearnaley, Tony Elliott, Gerhardt Attard, Noel W. Clarke, Melissa R. Spears, J. Martin Russell, Chris Parker, Jim Barber, Alison Birtle, Johann S. de Bono, Narayanan Srihari, Francesca Schiavone, Joe M. O'Sullivan, Malcolm David Mason, Isabel Syndikus, Jan Wallace, Mahesh K. B. Parmar, Nicholas D. James, A.W.S. Ritchie, Daniel S. Engeler, Delia Pudney
MPORTANCE:\ud \ud The natural history of patients with newly diagnosed high-risk nonmetastatic (M0) prostate cancer receiving hormone therapy (HT) either alone or with standard-of-care radiotherapy (RT) is not well documented. Furthermore, no clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e18432d25afd0d6774397b9ddf36c64
https://orca.cardiff.ac.uk/id/eprint/89456/1/coi150083.pdf
https://orca.cardiff.ac.uk/id/eprint/89456/1/coi150083.pdf